Non-small cell lung cancer
RecruitingStudy on the Safety and Effectiveness of Nivolumab, Pembrolizumab, and Cemiplimab with Radiotherapy for Stage IV Non-Small Cell Lung Cancer Patients
Study on the Safety and Effectiveness of Nivolumab, Pembrolizumab, and Cemiplimab with Radiotherapy for Stage IV Non-Small Cell Lung Cancer Patients
- Disease:Non-small cell lung cancer
- Substances:AtezolizumabCemiplimab+2
Norway- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Oslo University Hospital HF











